Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SXTP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.01% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.71M USD | Price to earnings Ratio - | 1Y Target Price 17 |
Price to earnings Ratio - | 1Y Target Price 17 | ||
Volume (30-day avg) 59128 | Beta - | 52 Weeks Range 1.41 - 23.94 | Updated Date 04/1/2025 |
52 Weeks Range 1.41 - 23.94 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -48.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -794% |
Management Effectiveness
Return on Assets (TTM) -89.67% | Return on Equity (TTM) -181.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7422075 | Price to Sales(TTM) 3.98 |
Enterprise Value 7422075 | Price to Sales(TTM) 3.98 | ||
Enterprise Value to Revenue 14.77 | Enterprise Value to EBITDA 22.23 | Shares Outstanding 1472910 | Shares Floating 1282859 |
Shares Outstanding 1472910 | Shares Floating 1282859 | ||
Percent Insiders 4.33 | Percent Institutions 2.09 |
Analyst Ratings
Rating 4 | Target Price 3.4 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
60 Degrees Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
60 Degrees Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of products for infectious diseases. It was founded to address unmet medical needs in the prevention and treatment of diseases prevalent in travelers and deployed military personnel. Specific founding year and milestones require further research.
Core Business Areas
- Pharmaceutical Development and Commercialization: Focuses on developing and commercializing prescription medicines and over-the-counter products that addresses diseases prevalent in travelers.
Leadership and Structure
Details on leadership team and organizational structure require further research. Usually involves a CEO, CFO, CSO, and board of directors.
Top Products and Market Share
Key Offerings
- Arakoda: Arakoda is a prescription medicine used to prevent malaria. Specific market share data requires further research. Competitors include drugs containing Atovaquone/Proguanil, Mefloquine, Doxycycline, and Tafenoquine. Sales have been limited and Arakoda is only sold in the United States.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, driven by innovation, regulatory approvals, and market access. The infectious disease segment faces increasing challenges due to antimicrobial resistance and emerging pathogens.
Positioning
60 Degrees Pharmaceuticals focuses on niche markets within infectious diseases, specifically travel-related illnesses, giving them a specialized position. Its competitive advantage lies in its targeted product development. Further research is required to determine their market leading position.
Total Addressable Market (TAM)
TAM for malaria prophylaxis is substantial, driven by international travel and military deployments. 60 Degrees Pharmaceuticals' positioning depends on Arakoda's market penetration and acceptance. Specific values requires futher market research.
Upturn SWOT Analysis
Strengths
- Focus on niche infectious disease market
- Proprietary drug development capabilities
- FDA-approved product (Arakoda)
Weaknesses
- Limited product portfolio
- High reliance on a single product (Arakoda)
- Small company size and limited resources
- Dependence on Sales within the United States.
Opportunities
- Expansion into new geographic markets
- Development of new products for other infectious diseases
- Partnerships with larger pharmaceutical companies
- Increasing global travel and military deployments driving demand for prophylactic treatments
Threats
- Competition from established pharmaceutical companies
- Generic erosion of Arakoda
- Changes in travel patterns or military deployment strategies
- Unfavorable regulatory changes
- Emergence of drug-resistant malaria strains
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Sanofi (SNY)
- Mylan (MYL) (now Viatris, VTRS)
Competitive Landscape
60 Degrees Pharmaceuticals faces significant competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Its advantage lies in its specialization and focus on a specific market niche.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Analysis of historical growth trends requires access to financial data over the past several years. Unavailable at this time.
Future Projections: Future growth projections require analyst estimates and company guidance. Unavailable at this time.
Recent Initiatives: Information on recent strategic initiatives requires further research. Likely initiatives include expanding market reach for Arakoda and developing new products.
Summary
60 Degrees Pharmaceuticals is a small company with a focus on niche infectious disease market. It has an FDA-approved product, Arakoda, for malaria prophylaxis, but faces significant competition from larger pharmaceutical companies. The company's success depends on expanding the market reach of Arakoda and developing new products. Sales are dependent on the United States market.
Similar Companies
- GSK
- SNY
- VTRS
Sources and Disclaimers
Data Sources:
- SEC Filings (if available)
- Company Website
- Industry Reports
- Analyst Reports (if available)
Disclaimers:
The information provided is based on limited publicly available information and may not be entirely accurate or complete. This analysis is not financial advice, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 60 Degrees Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2023-07-12 | Chairman, CEO & President Dr. Geoffrey Stuart Dow Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.60degreespharma.com |
Full time employees - | Website https://www.60degreespharma.com | ||
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.